(Adds details, background)
Nov 30 (Reuters) - Eli Lilly and Co's LLY.N COVID-19
drug bebtelovimab is not currently authorized for emergency use
in the United States, the Food and Drug Administration said,
citing it is not expected to neutralize the dominant BQ.1 and
BQ.1.1 subvariants of Omicron.
Wednesday's announcement takes away authorization from the
last COVID-19 monoclonal antibody treatment, leaving Pfizer
Inc's PFE.N antiviral drug Paxlovid, Merck's MRK.N Lagevrio
and Gilead Sciences' GILD.O Veklury as treatments for the
disease, besides convalescent plasma for some patients.
AstraZeneca Plc's AZN.L monoclonal antibody Evusheld is
also authorized for protection against COVID-19 infection in
some people.
Eli Lilly and its authorized distributors have paused
commercial distribution of the monoclonal antibody until further
notice from the agency, while the U.S. government has also
paused fulfillment of any pending requests under its scheme to
help uninsured and underinsured Americans access the drug.
The drug, which was discovered by Abcellera ABCL.O and
commercialized by Eli Lilly, received an authorization from the
FDA in February.
BQ.1 and BQ.1.1 have become the dominant strains in the
United States after a steady increase in prevalence over the
last two months, surpassing Omicron's BA.5 sub-variant, which
had driven cases earlier in the year.
The subvariants accounted for around 57% of the cases
nationally, as per government data last week.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj
Kalluvila)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))